NMTRQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NMTRQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. 9 Meters Biopharma's shares outstanding for the quarter that ended in Mar. 2023 was 14.34 Mil.
9 Meters Biopharma's quarterly shares outstanding increased from Dec. 2022 (13.04 Mil) to Mar. 2023 (14.34 Mil). It means 9 Meters Biopharma issued new shares from Dec. 2022 to Mar. 2023 .
9 Meters Biopharma's annual shares outstanding increased from Dec. 2021 (12.91 Mil) to Dec. 2022 (13.04 Mil). It means 9 Meters Biopharma issued new shares from Dec. 2021 to Dec. 2022 .
The historical data trend for 9 Meters Biopharma's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
9 Meters Biopharma Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 1.30 | 1.97 | 10.23 | 12.91 | 13.04 |
9 Meters Biopharma Quarterly Data | ||||||||||||||||||||
Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 12.91 | 12.96 | 12.96 | 13.04 | 14.34 |
For the Biotechnology subindustry, 9 Meters Biopharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where 9 Meters Biopharma's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
9 Meters Biopharma (OTCPK:NMTRQ) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of 9 Meters Biopharma's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
Bethany Sensenig | officer: Chief Financial Officer | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
John Temperato | director, officer: Chief Executive Officer | C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511 |
Mark A Sirgo | director | C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607 |
Michael T. Constantino | director | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Samantha Ventimiglia | director | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Edward J Sitar | officer: Chief Financial Officer | 39 FLAMING ARROW ROAD, MAHWAH NJ 07430 |
Orbimed Israel Biofund Gp Limited Partnership | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
Yehuda Michael Rice | director | 155 WALNUT STREET, ENGLEWOOD NJ 07631 |
Nissim Darvish | director, 10 percent owner | C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Orbimed Israel Gp Ltd. | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629 |
Sandeep Laumas | director, officer: Executive Chairman | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
Jay P. Madan | director, officer: President | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
Roy Proujansky | director | 144 PAU NEL DRIVE, LANDENBERG PA 19350 |
Christopher P. Prior | director, officer: Chief Executive Officer | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
June Sherie Almenoff | officer: COO and Chief Medical Officer | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 02-25-2022
By ACCESSWIRE ACCESSWIRE • 10-24-2022
By ACCESSWIRE ACCESSWIRE • 03-01-2022
By ACCESSWIRE ACCESSWIRE • 04-20-2022
By ACCESSWIRE ACCESSWIRE • 03-21-2022
By ACCESSWIRE ACCESSWIRE • 04-13-2022
By ACCESSWIRE ACCESSWIRE • 06-14-2022
By ACCESSWIRE ACCESSWIRE • 05-16-2023
By ACCESSWIRE ACCESSWIRE • 05-18-2022
By ACCESSWIRE ACCESSWIRE • 07-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.